Press Releases

611, 2018

Yuhan signs $1.25 billion licensing deal with Janssen

By genosco| 2018-11-06T10:00:00+00:00 November 6th, 2018|

Lasertinib(GNS-1480), discovered by Genosco, was out-licensed to Janssen.

306, 2018

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

By genosco| 2020-02-28T15:57:22+00:00 June 3rd, 2018|

Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.

306, 2018

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

By genosco| 2018-06-03T09:15:13+00:00 June 3rd, 2018|

1605, 2018

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448(GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

By genosco| 2018-06-04T12:19:41+00:00 May 16th, 2018|

Business Wire * May 16, 2018; Abstract - https://meetinglibrary.asco.org/record/161036/abstract

We are always open to new potential opportunities to establish strategic collaborations.

Genosco’s pipelines consist of 2 assets in Phase II, 1 asset in Phase I and multiple preclinical programs.

Genosco is a clinical-stage biotechnology company pursuing the discovery and development of novel small-molecule drugs to treat patients with unmet medical needs.

Press Releases

Yuhan signs $1.25 billion licensing deal with Janssen

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448(GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018